PubMed Health⌕ Search

PubMed · 10625985

Immune dysfunction in trauma.

Abstract

This article documents that all immunomodulation strategies for patients sustaining traumatic injury are still under intense investigation. Although we can speculate that combination strategies may be more beneficial than single-agent immunomodulation approaches, comprehensive clinical studies are required to determine efficacious immune therapy for trauma patients. The only strategy available to clinicians caring for trauma patients is immunonutrition, and this should be strongly considered as a rational approach to improve immune function and reduce septic complications in critically ill or injured patients.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

L M Napolitano, E Faist, M W Wichmann, R Coimbra. 1999. Immune dysfunction in trauma.. https://doi.org/10.1016/s0039-6109(05)70084-0

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

DNA immunomodulation of asthma.

This is an exciting time in the chronology of asthma and allergic diseases. Although the pharmacopeia for treatment of these diseases has advanced greatly, most of our current therapies are aimed at the symptoms, rather than the underlying mechanism. Immunotherapy remains the only therapeutic modality that addresses the underlying mechanism, albeit by effects are still not fully understood. The approaches summarized in this chapter, alone or in combination, may yet allow one to reverse the atopic state. Meanwhile, other innovative DNA-based approaches are being developed, including the use of allergen DNA with or without CpG. Because most of the Th2 cytokines are on chromosome 5, the completion of the human genome project may open whole new venues of research aimed at controlling these cytokines at the chromosomal level.

Adjuvants, Immunologic↗

Di-(2-ethylhexyl) phthalate possesses an adjuvant effect in a subcutaneous injection model with BALB/c mice.

The prevalence of allergic airway diseases is rapidly increasing in Western Europe and North America and the introduction of anthropogenic chemicals may explain a part of this increase. Recently, our group found that degradation products from several commonly used phthalate plasticizers possess adjuvant activity in an animal model. Mono-2-ethylhexyl phthalate, which is the degradation product of di-(2-ethylhexyl) phthalate (DEHP), was among these substances. These findings prompted the study of the adjuvant activity of the parent compound itself. Thus, DEHP was studied in a model using ovalbumin (OA) as the model antigen. OA was injected subcutaneously in the neck region of BALB/cJ mice with or without DEHP. The levels of OA-specific IgE, IgG1 and IgG2a antibodies in sera were measured by ELISA. Adjuvant effect, defined as a statistically significant increase in antibody level, was observed with IgG1 at a concentration of 2000 microg DEHP/ml after both one and two boosters.

Adjuvants, Immunologic↗